Stockwinners Market Radar for October 10, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:00 EDT Plutonian Acquisition to merge with Big Tree Cloud International - Big Tree Cloud International announced that they have entered into a definitive merger agreement that will result in Big Tree Cloud to be operated under a holding entity named Big Tree Cloud Holdings Limited, an exempted company incorporated in Cayman Islands and to be traded on the Nasdaq Stock Market. The Proposed Transaction reflects an initial equity value of approximately $500M.

19:15 EDT Opendoor Technologies director Wu sells 500,000 common shares - In a regulatory filing, Opendoor Technologies director Eric Chung-Wei Wu disclosed the sale of 500,000 common shares of the company on October 9 at a price of $2.3981 per share.

19:01 EDT MediciNova discloses notice of allowance for new patent on MN-166 + Riluzole - MediciNova "announced that it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers the combination of MN-166, or ibudilast, and riluzole for the treatment of amyotrophic lateral sclerosis. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than November 2035. The allowed claims cover the use of the combination of MN-166 and riluzole for treating a patient diagnosed with ALS when administered in a tablet, a capsule, or a liquid dosage form. The allowed claims specifically cover the use of the combination of MN-166 and riluzole for slowing progression of disease in a patient diagnosed with ALS when administered in a tablet, a capsule, or a liquid dosage form. The allowed claims cover a wide range of doses and a range of dosing regimens for both MN-166 and riluzole."

18:55 EDT Apple COO sells $12.4M in common stock - In a regulatory filing, Apple disclosed that its COO Jeffrey Willimas sold 69.8K shares of common stock on October 6th in a total transaction size of $12.4M.

18:25 EDT Gatos Silver reports Q3 silver production of 2.33M oz vs. 2.70M oz last year - Dale Andres, CEO of Gatos Silver, commented: "The CLG mine achieved strong production results in the third quarter, with the mill equaling the record throughput rate achieved last quarter. Consistent with the first half of the year, silver equivalent production in the third quarter and nine months tracked to the high end of our 2023 production guidance range. We are continuing to progress further life extension opportunities beyond 2030 by advancing conversion drilling of the South-East Deeps inferred resource and ramping up exploration efforts on near mine targets in the Los Gatos district."

17:35 EDT Progress Software gets SEC subpoena seeking information on MOVEit Vulnerability - In a regulatory filing, Progress announced that it received a subpoena from the SEC seeking various documents and information relating to the MOVEit Vulnerability. As described in the cover letter accompanying the subpoena, at this stage, the SEC investigation is a fact-finding inquiry, the investigation does not mean that Progress or anyone else has violated federal securities laws, and the investigation does not mean that the SEC has a negative opinion of any person, entity, or security. Progress intends to cooperate fully with the SEC in its investigation.

17:01 EDT SilverCrest reports Q3 gold recovered 15,700 ounces - The company: Recovered 15,700 ounces of gold and 1.49 million ounces of silver, or 2.74 million silver equivalent ounces2; Sold 14,500 ounces of gold at an average realized price of $1,931/oz and 1.53 million ounces of silver at an average realized price of $23.41/oz, or approximately 2.68 million AgEq ounces sold generating $63.8 million of revenue. N. Eric Fier, CEO, commented, "Las Chispas continued to perform well in Q3, 2023 with 2.68 million oz AgEq sold for a total of 7.69 million oz AgEq sold in the first nine months of the year. This positions us to deliver on our 2023 guidance of 9.8-10.2 million oz AgEq sold. In August 2023, we filed and launched a Normal Course Issuer Bid and during the remainder of the quarter spent $7.1 million to buy back 1.5 million shares. This demonstrates our financial strength and commitment to return shareholder capital and to continue to invest in our unique and high-quality project. We remain well funded to execute on our Las Chispas growth initiatives with eight drill rigs operating and $81.7 million in treasury holdings ($70.0 million cash and $11.7 million bullion) at the end of the quarter, an increase from $59 million at the end of Q2, 2023."

16:48 EDT Incyte brazilian affiliate submits authorization for pemigatinib to ANVISA - Knight Therapeutics announced that its Brazilian affiliate, United Medical, has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2, or FGFR2, fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Marketing authorization applications for pemigatinib have also been submitted previously in Colombia, Mexico and Argentina. Cholangiocarcinoma is the malignant neoplasm of the primary biliary tract, being the intrahepatic type localized in the biliary duct ramifications inside the liver. This kind of tumor is considered rare, and more than 50% of the patients are diagnosed in advanced disease stages. Knight has also submitted marketing authorization applications for tafasitamab in Colombia, Mexico and Argentina.

16:41 EDT Rayonier Advanced Materials targets $325M in annual EBITDA over next 5 years - Rayonier Advanced Materials outlined its financial growth strategy during the 2023 Investor Day event earlier today. Key highlights of the presentation include the company's outlook as follows: "Core Cellulose Specialties business expected to benefit from recent capacity closure in the industry. Focus on generating free cash flow and repaying debt to position the Company to refinance its 2026 Notes in 2024. Investments to expand Biomaterials business provide compelling growth prospects financed with low-cost capital. Conducting strategic review of Temiscaming site including a potential sale of non-core businesses with proceeds expected to be applied toward debt reduction. Executing strategy to minimize negative EBITDA impact of commodity viscose and paper pulp products. Demonstrating a willingness to curtail production based on market conditions. Near-term hurdles with expected lower third-quarter results and guidance for the full year. A more detailed update to be provided at the next quarter earnings call in early November. Financial vision centered on achieving $325 million in annual EBITDA over the next five years."

16:40 EDT Novo Nordisk to stop kidney outcomes trial FLOW - Novo Nordisk announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee concluding that the results from an interim analysis met certain pre-specified criteria for stopping the trial early for efficacy. Based on the decision to stop the trial at interim, the process of closing the trial will be initiated. To protect the integrity of the trial, Novo Nordisk remains blinded to the results until trial completion. Novo Nordisk expects that FLOW will read out during the first half year of 2024.

16:32 EDT 23andMe discloses user accounts data breach - 23andMe Holding Co. recently learned that certain profile information, which a customer creates and chooses to share with their genetic relatives in the DNA Relatives feature, was accessed from individual 23andMe.com accounts without the account users' authorization. Based on 23andMe's investigation, the company does not have any indication at this time that there has been a data security incident within its systems, or that 23andMe was the source of the account credentials used in these attacks. While the investigation is ongoing, the company believes the threat actor was able to access certain accounts in instances usernames and passwords that were used on 23andMe.com were the same as those used on other websites that had been previously compromised or otherwise available. 23andMe undertook immediate action in accordance with its incident response plan, including taking affirmative security measures to mitigate any potential impact of the incident, working to validate whether data that was accessed was legitimate data from the Website, and determining the full scope of data accessed by unauthorized individuals. 23andMe has retained third-party forensic experts to assist in an investigation of the cause and scope of the incident, and in mitigating and remediating the impact of the incident. 23andMe is fully cooperating with federal law enforcement in relation to this incident. 23andMe is currently working to confirm the scope of data accessed, and is investigating the nature of the personal data in question and any related legal obligations. 23andMe's investigation into these matters is preliminary and on going, and 23andMe is still discerning the implications of the incident.

16:27 EDT Silk Road Medical CEO Erica Rogers plans to retire, following succession process - Silk Road Medica announced that CEO Erica Rogers plans to retire from the Company following the completion of a succession process. The Company is working with Spencer Stuart, a leading executive search firm. To ensure a smooth transition, Ms. Rogers will remain as President and CEO of the Company until her successor is appointed. "

16:24 EDT SuRo Capital reports preliminary Q3 net assets per share $7.35 - SuRo Capital provided the following preliminary update on its investment portfolio for the third quarter ended September 30. As previously reported, SuRo Capital's net assets totaled approximately $186.7M, or $7.35 per share at June 30 and approximately $221.8M, or $7.83 per share at September 30. As of September 30, SuRo Capital's net asset value is estimated to be between $8.15 to $8.65 per share.

16:22 EDT Invesco reports preliminary AUM down 2.6% to $1.487T as of September 30 - Invesco reported preliminary month-end assets under management, or AUM, of $1.4873T, a decrease of 2.6% versus previous month-end. The firm delivered net long-term inflows of $1.6B in the month. Non-management fee earning net inflows were $2.7B and money market net inflows were $2.4B. AUM was negatively impacted by unfavorable market returns which decreased AUM by $43B. FX and reinvested distributions decreased AUM by $3.7B. Preliminary average total AUM for the quarter through September 30 were $1.5287T, and preliminary average active AUM for the quarter through September 30 were $994.5B.

16:19 EDT Global System Dynamics receives noncompliance notification from Nasdaq - Global System Dynamics announced that it has received written notification from the listing qualifications staff of Nasdaq indicating that the company has not regained compliance with the minimum market value of listed securities of $35M required for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550.

16:18 EDT Alamo Group acquires 100% of outstanding equity of Royal Truck & Equipment - Alamo Group announced that it has acquired 100% of the outstanding equity capital of Royal Truck & Equipment, a leading manufacturer of truck mounted highway attenuator trucks and other specialty trucks and equipment for the highway infrastructure and traffic control market. Royal Truck's annual revenue was approximately $40M in 2022 and the company had trailing twelve-month revenue of approximately $44M as of the end of August, 2023. Royal Truck prides itself on develops innovative products designed to improve road work zone safety. The company is based in Shoemakersville, Pennsylvania and has approximately 50 employees.

16:17 EDT Bank of Montreal announces retirement of Dan Barclay - BMO Financial Group announced the upcoming retirement of its CEO & Group Head, Capital Markets, Dan Barclay, and the appointment of Alan Tannenbaum into the role. After a 32-year investment banking career, Barclay will transition to a role as senior advisor to the CEO. Tannenbaum will also join the bank's executive committee. Both changes are effective November 1. Tannenbaum will lead BMO Capital Markets and provide strategic direction on global markets and investment and corporate banking customer segments. He will report to Darryl White, CEO, BMO Financial Group. Tannenbaum will be succeeded in his current role by Brad Chapin who will serve as Interim Global Head, Investment & Corporate Banking.

16:16 EDT TriNet announces collaboration with Healthee - At the HR Technology Conference & Exposition 2023, TriNet announced a collaboration with Healthee, an industry leader in AI-powered digital solutions that enhance the health and wellness experience. TriNet's partnership with Healthee will provide TriNet customers with exclusive access to Healthee's market leading solutions delivered directly to TriNet's customers. TriNet's strategic relationship with Healthee provides direct access to modern tools for benefits navigation, which help employees pick the right benefits for their families and better utilize their existing benefits.

16:09 EDT Tempest Therapeutics to report new updated TPST-1120 data for HCC treatment - Tempest Therapeutics announced the company plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with atezolizumab and bevacizumab in first-line treatment of hepatocellular carcinoma HCC in a premarket press release on Wednesday, October 11 followed by a webcasted conference call with associated slide presentation at 8:30 a.m. ET on Wednesday, October 11.

16:07 EDT Viking announces presentation on clinical trial of VK2735 at ObesityWeek 2023 - Viking Therapeutics announced that data from the company's Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735 will be highlighted as part of an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors in development for the potential treatment of various metabolic disorders such as obesity. ObesityWeek 2023 is being held October 14-17 at the Kay Bailey Hutchison Convention Center in Dallas, Texas. The oral presentation will provide an overview of previously reported results from Viking's Phase 1 SAD/MAD study of VK2735 in healthy volunteers with a BMI greater than or equal to30. In addition, new findings related to the impact of VK2735 on subjects' liver fat content and plasma lipid levels will be reported.

16:06 EDT Virtus Investment reports September-end AUM $162.5B vs. $169.4B last month - Virtus Investment "reported preliminary assets under management of $162.5 billion as of September 30, 2023. The decrease from June 30, 2023 primarily reflects market depreciation and net outflows in open-end funds and institutional accounts, partially offset by net inflows in retail separate accounts. In addition, the company provided services to $2.5 billion of other fee-earning assets, which are not included in assets under management."

16:05 EDT Alliance Entertainment gets late filing Nasdaq notice - Alliance Entertainment Holding announced it received a written notice from The Nasdaq Stock Market on October 4, , it no longer complies with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to file an annual report on Form 10-K for the year ended June 30 with the Securities and Exchange Commission by the required due date. This notification has no immediate effect on the listing of the Company's shares on Nasdaq. Under Nasdaq Rules the Company has 60 calendar days from receipt of the Notice to submit a plan to regain compliance with the Rule. If Nasdaq accepts the Company's plan, Nasdaq may grant an exception of up to 180 calendar days from the due date of the 10-K, or until March 27, 2024, to regain compliance. The Company is in the process of preparing the plan to regain compliance and finalizing the financial statements for the year ending June 30.The Company will submit the plan to regain compliance and file its Annual Report as soon as possible.

16:02 EDT Lattice Semiconductor's FPGA solutions selected for Mazda's new CX-60 and CX-90 - Lattice Semiconductor (LSCC) announced its award-winning Lattice FPGAs now enable advanced driver experiences on Mazda Motor Corporation's (MZDAY) new CX-60 and CX-90 models. The Mazda crossover SUVs leverage a cutting-edge interface bridging solution based on multiple low power Lattice FPGAs to provide safety-critical Advanced Driver Assistance System side radar applications made by Furukawa Electric, including a wider detection range, improved detection accuracy, and spatial recognition performance, without sacrificing vehicle performance.

16:00 EDT Barings Corporate Investors raises quarterly dividend 5.7% to 37c per share - The Board of Trustees of Barings Corporate Investors announced that it has declared a quarterly dividend of 37c per share payable on November 17, 2023, to shareholders of record on November 6, 2023. Clifford Noreen, Chairman, stated, "We are pleased to announce an increase of $0.02 per share to the Trust's quarterly cash dividend, which represents a 5.7% increase over the previous dividend of $0.35 per share and a 54.2% increase since we started raising the dividend from $0.24 per share approximately one year ago. Significant growth in net investment income, due primarily to increases in base rates for our floating rate holdings, has led the Board of Trustees to declare the fifth consecutive increase to the quarterly dividend, further benefiting shareholders."

13:53 EDT Mallinckrodt announces U.S. court approval for financial restructuring plan - Mallinckrodt plc (MNKTQ) announced that its Plan of Reorganization has been confirmed by the U.S. Bankruptcy Court for the District of Delaware, positioning the company to emerge from Chapter 11 by the end of the year. "Mallinckrodt's Plan of Reorganization is supported by a substantial majority of its financial stakeholders, including holders of approximately 90% of its first and second lien debt and the Opioid Master Disbursement Trust II, as part of a previously announced Restructuring Support Agreement. Upon emergence, Mallinckrodt will eliminate approximately $1.9B of total funded debt and ownership of the business will transition to the Company's creditors. In addition, the Company's obligations to the Trust will be satisfied on terms agreed with the Trust, including through a $250M payment made to the Trust prior to the Chapter 11 filing, among other consideration. As previously announced, Mallinckrodt's directors initiated examinership proceedings in Ireland on September 20, 2023. These proceedings, which are required to implement certain Irish law aspects of the Company's financial restructuring and allow for emergence, are expected to take between two and three months to complete. Mallinckrodt expects to formally emerge from Chapter 11 in the fourth quarter of 2023, following the completion of the Irish examinership proceedings and once all conditions of the Plan are satisfied or waived. Until that time, the Company remains under the U.S. Bankruptcy Court's jurisdiction," the company stated. Siggi Olafsson, President and CEO of Mallinckrodt, said, "We are pleased to achieve this important milestone and look forward to moving ahead as a stronger company. With substantially less debt and additional financial flexibility, we will be better positioned for the future as we continue delivering therapies that improve outcomes for patients with severe and critical conditions and executing on our strategic priorities. We appreciate the significant support of our financial stakeholders, which has enabled us to reach this point quickly and without interruption to our patients, customers, employees or business partners."

13:37 EDT GM Canada announces tentative agreement with Unifor - General Motors of Canada stated that on October 10 at 1:00 p.m. EDT, GM Canada reached a tentative agreement with Unifor covering approximately 4,200 represented employees at its St. Catharines Propulsion Plant, Oshawa Assembly & Operations, and the Woodstock Parts Distribution Centre. "Work will resume at all three facilities this afternoon. This record agreement, subject to member ratification, recognizes the many contributions of our represented team members with significant increases in wages, benefits and job security while building on GM's historic investments in Canadian manufacturing. To respect Unifor's ratification process, more details will be shared at the appropriate time," GM Canada stated.

13:29 EDT Alight director Massey buys $322,490 in company shares - Director of Alight, Richard Massey, disclosed in a regulatory filing that he had purchased 50,000 shares of company stock at $6.45 per share on October 5, for a total transaction amount of $322,490.

13:02 EDT IMAX expands partnership with NCG Cinemas for three IMAX locations - IMAX Corporation and U.S. exhibitor NCG Cinemas announced a new agreement for three IMAX with Laser Systems across the U.S. The deal will expand IMAX's existing footprint with NCG Cinemas with two new IMAX locations in Tennessee and Georgia as well as an upgraded location in Michigan. Planning for the construction of the new standalone IMAX theatre in Kingsport, Tennessee begins this week, and is expected to open to the public in March 2025.

12:25 EDT SCWorx announces shareholder approval of reverse stock split - SCWorx Corp. announced the conclusion of its 2023 Annual Meeting of Stockholders Shareholders embraced the reverse stock split and showing overwhelming support for the company, the company said in a statement. Following the Meeting, the company's Board of Directors approved a final ratio of 15-for-1 for the reverse stock split , which was within the parameters approved by the shareholders. The Split is expected to become effective at market open on October 11, 2023, pending confirmation by the Depository Trust Company and the Nasdaq. The company's common stock will continue to trade on the Nasdaq Capital Market under the company's existing trading symbol, "WORX." The split reduces the number of shares of the company's outstanding common stock from approximately 17.9 million shares to approximately 1.2 million shares, subject to adjustment due to fractional shares.

12:16 EDT MSCI announces acquisition of Trove Research; financial terms not disclosed - MSCI announced it has signed a purchase agreement to acquire Trove Research, a specialist data, analysis and advisory firm. Henry Fernandez, Chairman and CEO, MSCI, said: "The voluntary carbon market has a key role to play in helping the world achieve net-zero emissions while helping our clients navigate the transition. Trove Research offers unique data and insights on how the market works and what can be done to improve it. By combining these tools with our integrated franchise, diverse client base, and wide range of capabilities, MSCI will strengthen its position as a leading provider of climate-related investment solutions." The terms of the transaction were not disclosed and the financial impact of the transaction is not expected to be material to MSCI. The transaction is expected to close this quarter, subject to customary closing conditions. Trove Research's financial results will be presented as part of MSCI's ESG & Climate reportable segment.

12:08 EDT Adobe showcases Adobe GenStudio at Adobe MAX - Today, at Adobe MAX, Adobe showcased Adobe GenStudio, a new end-to-end solution that brings together applications across Creative Cloud, Express and Experience Cloud, with Firefly generative AI at the core. "Demand for content shows no signs of slowing, with nearly two-thirds of customer experience professionals expecting demand to rise five-fold over the next two years," said Amit Ahuja, senior vice president, Digital Experience Business at Adobe. "Adobe GenStudio can take tasks that would normally take hours or days down to minutes, providing speed without any compromise to quality or brand consistency."

12:06 EDT Adobe releases next generation of Firefly models - Adobe unveiled Adobe Firefly Image 2 Model, Adobe Firefly Vector Model and Adobe Firefly Design Model. "Our rapid, continuous pace of Firefly innovation continues with imaging, design and vector generation advancements - three new models that set new industry standards for output quality and user control," said Ely Greenfield, chief technology officer, Digital Media at Adobe. "Firefly continues to offer the world's best combination of visual capabilities, designed to be commercially safe, enables transformative new creative workflows across Adobe apps." Users have generated over 3 billion images with Firefly's initial model since its beta launch in March, Adobe noted.

12:04 EDT Coca-Cola, AEG renew multiyear partnership agreement - Coca-Cola North America and local bottling partner, Reyes Coca-Cola Bottling, have renewed a multiyear partnership with AEG, a sports and live entertainment company. Brokered by AEG Global Partnerships, the new agreement between AEG and Coca-Cola strategically aligns the brands and will bring a brand new "Coke Studio" to Crypto.com Arena. The new studio will offer visitors immersive fan experiences and music-driven activations. The deal also continues Coca-Cola's longstanding Founding Partner status at Crypto.com Arena and L.A. LIVE, Peacock Theater, and Dignity Health Sports Park and makes Coca-Cola the exclusive soft drink partner of an increased number of leading AEG Presents music festivals.

12:00 EDT Lithium Argentina falls -6.4% - Lithium Argentina is down -6.4%, or -51c to $7.43.

12:00 EDT Twin Ridge Capital Acquisition falls -9.1% - Twin Ridge Capital Acquisition is down -9.1%, or -95c to $9.50.

12:00 EDT PGT Innovations rises 20.2% - PGT Innovations is up 20.2%, or $5.30 to $31.50.

11:49 EDT LVMH 'confident' in continuation of growth - LVMH said: "In an uncertain economic and geopolitical environment, the Group is confident in the continuation of its growth and will maintain a strategy focused on continuously enhancing the desirability of its brands, drawing on the authenticity and quality of its products, excellence in distribution and agile organization."

11:17 EDT MAIA Biotechnology announces 49 patients dosed in THIO-101 trial - MAIA Biotechnology announced that 49 patients have been dosed in MAIA's Phase 2 clinical trial, THIO-101, evaluating THIO in sequential combination with an immune checkpoint inhibitor in patients with advanced Non-Small Cell Lung Cancer. "In feedback received from the clinical trial investigators, the encouraging efficacy observed in dosed patients is prompting physicians to speed up trial enrollment even further. Following U.S. Food and Drug Administration clearance of the Investigational New Drug application, we expect to more than double the number of sites in the near future," said Vlad Vitoc, CEO. "We are pleased with the pace of enrollment for THIO-101, our go-to-market trial, which is currently exceeding the average enrollment pace in similar NSCLC trials. We look forward to sharing preliminary safety and efficacy data in the coming weeks."

11:02 EDT Boeing reports 105 commercial airplane deliveries in Q3 - Boeing announced major program deliveries across its commercial and defense operations for the third quarter of 2023, reporting 105 total commercial airplanes programs deliveries in Q3, including 70 deliveries of 737 jets. The company noted that it will provide detailed third-quarter financial results on October 25.

10:47 EDT Delaware Supreme Court rules Energy Transfer must pay Williams $495M - The Delaware Supreme Court ruled in favor of Williams (WMB), saying Energy Transfer LP (ET) must pay the company a total of $495M for walking away from their planned merger. The court said, "The parties have spent the better part of a decade litigating over various fees to which they argue they are entitled under the Merger Agreement. ETE continues to assert its entitlement to a $1.48 billion breakup fee, despite being the party who terminated the Merger. It also disputes that it must pay Williams a $410 million reimbursement fee, which it was required to pay if the Merger failed and certain conditions were met. Finally, ETE argues that a related $85 million attorney's fee award is unreasonable. But we find no error with the Court of Chancery's well-reasoned opinions that hold that ETE is not entitled to an over-one-billion-dollar fee and find that ETE must pay Williams the $410 million reimbursement fee and the related $85 million in attorney's fees. The litigation between the parties over their failed merger has now come to an end." Reference Link

10:01 EDT Izea reports Q3 managed services bookings of $7.1M vs. $8.3M last year - IZEA Worldwide announced its Managed Services team recorded $7.1M in bookings in the third quarter of 2023, compared with $8.3M in the third quarter of 2022. The year-over-year bookings decline is attributed to the company parting ways with a large customer. However, when excluding bookings from the large customer from the comparison, bookings from ongoing customers grew by $1M for the quarter, or 17.3%, year-over-year, IZEA said.

10:00 EDT Wiley falls -8.1% - Wiley is down -8.1%, or -$2.82 to $31.81.

10:00 EDT Coherent rises 11.6% - Coherent is up 11.6%, or $3.61 to $34.61.

10:00 EDT StarTek rises 29.7% - StarTek is up 29.7%, or 97c to $4.23.

09:47 EDT Posco falls -5.0% - Posco is down -5.0%, or -$4.81 to $92.00.

09:47 EDT Spruce Power Holding rises 10.7% - Spruce Power Holding is up 10.7%, or 46c to $4.76.

09:47 EDT MiX Telematics rises 17.5% - MiX Telematics is up 17.5%, or 97c to $6.55.

09:40 EDT StarTek trading resumes

09:37 EDT Fast Acquisition Corp II trading halted, volatility trading pause

09:34 EDT Inspira Technologies enters distribution agreement with CIO MED GROUP - Inspira Technologies had signed a distribution agreement with CIO MED GROUP. The Agreement to potentially generate $28 million, mainly in recurring revenues from disposable kits over five years, subject to the receipt of regulatory approval. The parties will collaborate on the marketing and the deployment of the INSPIRA ART device line and disposable kits in Central America. This includes the INSPIRA ART100, a cardio-pulmonary bypass device, which was recently submitted for U.S. Food & Drug Administration clearance with an expected approval timeline of approximately six months, or the first half of 2024. In addition to the INSPIRA ART100 device intended for patients undergoing CPB procedures, the Agreement also includes both the flagship INSPIRA ART500 device and HYLA Blood Sensor Technology, as well as disposable kits to be used with these Inspira Technologies devices in the procedures.

09:27 EDT StarTek signs agreement to be acquired by CSP Management for $4.30 per share - Startek has entered into a definitive agreement to be acquired by funds managed by Capital Square Partners in an all-cash transaction with a total enterprise value of approximately $217M and total equity value of approximately $174M. CSP will acquire all shares of Startek common stock not already owned by CSP for $4.30 per share in cash. The purchase price represents a premium of approximately 32% to Startek's closing share price of $3.26 on October 9, and a premium of approximately 50% to the closing price of the shares. On July 18, , Startek received a preliminary non-binding proposal from CSP to acquire all shares of Startek common stock that it does not already own for $3.80 in cash per share. The Special Committee unanimously recommended that the Board approve the merger agreement. Subsequently, the Startek Board, based on the recommendation of the Special Committee, unanimously approved the merger agreement. The transaction is expected to close by the end of 2023. The transaction is not subject to any financing contingency. Upon completion of the transaction, Startek will no longer trade on the NYSE and will become a private company.

09:26 EDT Merit Medical launches expanded Maestro Microcatheter line - Merit Medical Systems announced the expansion of its Maestro Microcatheter product line to now include a new longer length for radial embolization procedures. The Maestro is part of a comprehensive offering of embolotherapy solutions, which includes Embosphere Microspheres, the most widely studied and clinically utilized round embolic on the market. Embolization is a minimally invasive procedure that blocks one or more blood vessels or abnormal vascular channels to treat a number of clinical conditions. The new 165-cm Maestro length will be available in 2.1F, 2.4F, 2.8F, and 2.9F catheter diameters to support a broad range of embolization procedures.

09:21 EDT Zentek announces pre-clinical testing of aptamer-based plaform technology - Zentek announced further pre-clinical testing of the aptamer-based platform technology by the Dr. Matthew Miller Lab. After initial promising results released on July 27th, 2023, which featured an aptamer therapeutic/prophylactic using the novel platform technology developed by the lab of Dr. Yingfu Li and tested by the team of Dr. Matthew Miller, further preclinical testing has been completed supporting this aptamer as a lead therapeutic target. An in vivo preclinical longevity of protection study was conducted to assess the safety and efficacy of the aptamer-based treatment over a period of 24 hours. This duration was chosen to mimic a suitable prophylactic use case that balances the convenience of a daily dose while maintaining complete protection. The study successfully demonstrated that the novel aptamer provided 24 hours of neutralizing protection against SARS-CoV-2 and improves the potential of the aptamer as a prophylactic in a setting that is both commercially and clinically relevant. The trial used three test groups of 10 mice, which were administered three separate treatments 24 hours prior to administering the virus: Group 1 - control that was administered saline; Group 2 - received the novel aptamer developed by the Li lab; Group 3 - received the S309 antibody treatment; the most effective antibody against SARS-CoV-2 variants that received emergency use approval/ After 24 hours, all mice received a lethal challenge of the original Wuhan strain of SARS-CoV-2. Viral titers were measured and histopathology was performed at the end of the 7-day study. The mice that received the aptamers showed no clinical signs of infection, similar to those that received the S309 antibody. A subsequent study was conducted to determine the minimal effective dose of the aptamer required to protect against a lethal challenge of SARS-CoV-2 - an important step in safety profile and resource efficiency optimization. Four separate groups of 10 mice were tested in the experiment: Group 1 - control that received saline; Group 2 - received the original aptamer dosage; Group 3 - received a 10-fold lower dose; Group 4 - received a 50-fold lower dose; After two hours, mice were challenged with a lethal dose of SARS-CoV-2 . The Group 2 mice that received 258 microM of aptamer were consistent with the previous tests reported on July 27th, where the aptamers provided sterilizing protection. Group 3, which received a ten-fold lower dose, showed no clinical markers of infection demonstrating that this lower aptamer dose still provided complete protection against SARS-CoV-2. Group 4 that received the lowest dose showed signs of infection similar to the control group suggesting that an optimum dosage is in the range of 25.8 microM through this delivery system. Based on these promising results, the next step will be to evaluate the aptamer's ability to protect against infection with the Omicron variant.

09:20 EDT Mogo to migrate to Oracle Cloud Infrastructure - Mogo (MOGO) announced that it has selected Oracle (ORCL) Cloud Infrastructure, or OCI, to accelerate innovation and support the long-term growth of the company's digital wealth platform.

09:19 EDT Trex Company names Brenda Lovcik CFO - Trex Company (TREX) announced that it has named Brenda Lovcik senior VP and CFO effective October 23. Most recently she served as CFO, global products, global supply chain and global FP&A at Johnson Controls (JCI).

09:17 EDT Capital Power to acquire 50.15% interest in Frederickson 1 Generating Station - Capital Powerhas executed an agreement to acquire a 50.15% ownership interest in the Frederickson 1 Generating Station rom Atlantic Power & Utilities for US$100 million. The other 49.85% is owned by Puget Sound Energy. Capital Power will finance the transaction using cash on hand and its credit facilities. The transaction is expected to close in the fourth quarter of 2023, subject to customary regulatory approvals and other closing adjustments and conditions. Frederickson 1 is a 265 MW natural gas-fired combined-cycle generating facility in Pierce County, Washington. The facility is well-positioned as a flexible and dispatchable resource that provides reliable power in support of the continuing energy transition to renewables in the region. Capital Power will operate and maintain the facility and bring to bear its deep knowledge and experience in plant operations and optimization and will receive an annual management fee under the operating arrangement with PSE.

09:16 EDT Micron introduces 16Gb DDR5 memory - Micron Technology has extended its industry-leading 1beta process node technology with the introduction of 16Gb DDR5 memory. With demonstrated in-system functionality at speeds up to 7,200 MT/s, Micron's 1beta DDR5 DRAM is now shipping to all data center and PC customers. Micron's 1beta-based DDR5 memory with advanced high-k CMOS device technology, 4-phase clocking and clock-sync provides up to a 50% performance uplift2 and 33% improvement in performance per watt over the previous generation.

09:16 EDT SLB, AWS and Shell collaborate to accelerate OSDU Data Platform adoption - SLB (SLB), Amazon (AMZN) Web Services, AWS, and Shell Global Solutions Nederland BV or Shell (SHEL) have signed a multi-year three-way collaboration agreement to deliver digital end-to-end workflows for Shell, using SLB subsurface solutions on AWS cloud infrastructure. The collaboration is intended to deliver high performance and cost efficient subsurface digital solutions, to be used by Shell and made available to the industry. The digital workflows will use the OSDU Data Platform standards to improve the positive customer experience by business users-increasing efficiency and collaboration, while producing better insights to Shell and the energy industry. T "This collaboration with Shell and SLB will set a new standard for application and data interoperability, to provide the best user experience at the lowest cost of operation," said Howard Gefen, General Manager - Energy & Utilities, AWS. "The combined capabilities across Shell, SLB, and AWS will not only ensure the delivery of value at scale, but will unlock areas of innovation where the collaboration will develop new approaches and solutions to the challenges faced in subsurface workflows seen across the energy industry."

09:15 EDT StarTek trading halted, news pending

09:13 EDT Sides Wealth Advisory Group launches with LPL Financial Strategic Wealth - LPL Financial announced that financial advisors Brock Hively, Josh Smeltzer, Aaron Gingrich, and Emily Sides, have joined LPL Financial to launch a new independent practice, Sides Wealth Advisory Group. They chose to affiliate with LPL's supported independence model, LPL Strategic Wealth Services, and reported having served approximately $900 million in advisory, brokerage and retirement plan assets*. They join LPL from RBC.

09:11 EDT Inspirato, TJH enter strategic partnership - Thomas James Homes, TJH, announces its strategic partnership with Inspirato Incorporated. As a key component of the relationship, Inspirato will provide TJH clients with 12 months of a complimentary Inspirato Travel Membership. This membership will allow clients to book travel within Inspirato's curated collection of 750+ luxury vacation options in 100+ locations around the world paying members-only rates as they travel. "We are thrilled to partner with Thomas James Homes, which provides homebuyers with access to lifestyles as vibrant and varied as the communities in which they build," said Dain Rasmussen, Senior Vice President of Sales at Inspirato. "Their clients share the same discerning tastes as Inspirato members, so there is a lot of synergy between our portfolio and the homes that TJH builds. We look forward to welcoming them on many Inspirato vacations where they will feel at home as they await their dream homes to be completed."

09:10 EDT Sage Group launches Sage Construction Management - Sage announced the expansion of its construction cloud suite. With the launch of Sage Construction Management, Sage adds cloud preconstruction and project management capabilities to its industry-leading construction portfolio. Sage Construction Management is built for collaboration and mobility so field, office, and external teams can share real-time project information and make quick, informed decisions. The solution is offered together with Sage Intacct Construction Financials as an end-to-end suite that enables operational and finance teams to align and work together towards improved job profitability.

09:09 EDT RCI Hospitality reports Q4 club & restaurant sales up 5.6% y-o-y - RCI Hospitality reported sales for its Nightclubs and Bombshells restaurants of $74.1M, an increase of 5.6% year over year, for Q4. Sales totaled $60.5M, an increase of 7.5% or $4.2M year-over-year. Contributing to the increase were $9.2M from FY22-FY23 acquisitions not in same-store sales and $0.8M from reformatted clubs not in SSS. This was partially offset by a SSS decline of 9.6% or $5.1M and a $0.7M decrease from clubs closed prior to 4Q23. Bombshells sales totaled $13.6M compared to $13.9M in 4Q22. The gaming and liquor license and building permit processes are continuing for the planned Rick's Cabaret Steakhouse & Casino and Bombshells Sports Casino in Central City, CO.

09:08 EDT Blue Water Biotech appoints Neil Campbell as president, CEO - Blue Water Biotech announced the appointments of Dr. Neil Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott Laboratories. Prior to joining Blue Water Biotech, Dr. Campbell was president, CEO and a director of Marizyme Inc. He also founded and served as chairman and CEO of Celios(R), a respiratory device company that was acquired by a private investment group. Prior to this, Dr. Campbell was the co-founder, president and CEO of Helomics, a personalized healthcare company focused on next-generation oncology and immune therapeutics and diagnostics. This company was acquired by a private equity investor. Dr. Campbell also held senior executive positions with SuperNova Diagnostics, EntreMed Pharmaceuticals and Life Technologies. Harmon replaces Jon Garfield, who has left the company. Mr. Harmon has served in a variety of roles, including chief financial officer, controller, chief executive officer and audit committee chairman. Immediately prior to joining Blue Water Biotech, he was an independent consultant who served in the outsourced CFO capacity for multiple publicly traded companies since 2008.

09:07 EDT Verizon, edX partner to accelerate skill building for tech careers - Verizon (VZ) announced the launch of a new online education portal with edX, a global online learning platform from 2U (TWOU), to help upskill and reskill Americans for today's fastest-growing jobs. As recent research reveals, one-third of workers don't have the foundational digital skills necessary to enter today's jobs. With no prior experience or college degree required, participants can register for Verizon Skill Forward to access self-paced, expert-led online courses designed by leading universities and industry experts in edX's partner network for 12 months at no cost, including dedicated courses in Spanish. "When you make quality education accessible to all, you give individuals the freedom to pave their own path," said Rose Stuckey Kirk, Senior Vice President and Chief Corporate Social Responsibility Officer for Verizon. "Through Verizon Skill Forward, we remain committed to bridging the digital divide and providing access to opportunities for economic advancement in under-resourced communities across the country, from the moment a student enters a classroom, to the moment they embark on the pursuit of a career and higher education."

09:05 EDT Maxeon Solar provides business update, announces 15% workforce reduction - Maxeon Solar provided a business update following the end of Q3, during which the Company's performance was impacted by reduced shipments to its largest distributed generation customer located in the U.S. and an industry-wide demand slowdown in the global DG markets. CEO Bill Mulligan commented, "our largest US DG customer breached their payment obligations under our current Master Supply Agreement and we paused shipments in late July as a result. While this customer has recently made several payments on their outstanding balance and is now close to becoming current, we continue to pause our shipments and engage in good faith towards resolution of certain ongoing claims of breach under the MSA. We do not have visibility into how quickly such resolution can be achieved...Instead of refurbishing our Fab 5 facility in the Philippines, which we now plan to utilize for the scale-up of our next-generation Maxeon 8 technology, we will convert our legacy Maxeon 3 capacity in the Philippines to Maxeon 7 technology. This will allow us to accelerate market introduction of world-record efficiency Maxeon 7 panels by several months and reduce capital expenditures by about $100M." Maxeon also plans to begin the preparation of its Fab 3 facility in Malaysia to install a TOPCon solar cell pilot line ahead of the start-up of the planned manufacturing facility in Albuquerque. Maxeon's Albuquerque solar cell and module factory remains on track. Restructuring actions are expected to result in a reduction of approximately 15% of the company's global workforce, with most of the reductions expected to occur by the end of the year.

09:03 EDT Capricor Therapeutics announces late-breaking presentations at WMS - Capricor Therapeutics announced data from two late-breaking posters presented at this year's 28th International Annual Congress of the World Muscle Society, WMS, which took place in Charleston, South Carolina, from October 3-7, 2023. Presentations included data from the two-year open label extension, OLE, of the HOPE-2 clinical trial highlighting the efficacy of Capricor's lead asset, CAP-1002 to treat patients with Duchenne muscular dystrophy, DMD, and preclinical data showing the potential of the Company's proprietary StealthX exosome platform to enhance the delivery of antisense oligonucleotides, ASOs. Late-Breaking Poster: Capricor's 24-Month HOPE-2 Results Show CAP-1002's Long-Term Safety and Efficacy in Patients with Late-Stage DMD. Data from the Company's HOPE-2 OLE study measured by the Performance of the Upper Limb showed a mean PUL 2.0 decline after 24-months of treatment with CAP-1002 was 2.8 points versus a 7.7-point decline on average observed over 24-months in the placebo patient group. The average rate of decline in CAP-1002 treated patients showed an attenuation of disease progression by approximately 64%. Additionally, CAP-1002 revealed clinically meaningful improvements in ameliorating cardiac function. The data showed that cardiac function, as measured by left ventricular ejection fraction by MRI at the 24-month timepoint, improved in 67% of patients, compared to a steady decline in a comparable natural history population. Late-Breaking Poster: StealthX Platform for Enhanced Exosome-Based ASO Delivery. One of the predominant strategies for treating DMD has been through the employment of antisense oligonucleotides to exclude exons resulting in DMD proteins with partially restored function. The main challenge of antisense drugs is to improve their delivery to target tissues. To overcome this challenge, a muscle-targeting moiety was engineered on the surface of the exosomes using Capricor's StealthX technology. The study results showed the presence of exosomes loaded with a labeled ASO in the lower limbs of mice 24 hours post-injection.

09:02 EDT Wallbridge Mining president, CEO Marz Kord to retire - Wallbridge Mining announced that Marz Kord is retiring from his role as President and CEO and director, effective immediately. Mr. Kord will remain employed until December 31, 2023 to support the management team through the management transition. In addition, Parviz Farsangi has decided to retire from the Board of Directors. Both Mr. Kord and Mr. Farsangi will continue as Advisors to the Company and the Board. Brian Penny, the Company's CFO, will assume the role of interim CEO and joins the Board as a director. Mary Montgomery will assume the role of interim CFO. Both appointments are effective immediately.

09:00 EDT Athersys trading resumes

08:50 EDT Grid Dynamics earns Infra, Database Migration to Microsoft Azure Specialization - Grid Dynamics Holdings has earned the Infra and Database Migration to Microsoft Azure Specialization from Microsoft. This specialization expands Grid Dynamics' participation in Microsoft's innovative Azure Migrate and Modernize program, showcasing yet again the company's exceptional technical capabilities. The program helps accelerate and simplify clients' migration & modernization of cloud workloads and includes a range of training, services, and financial support for transformation initiatives. As a member of this exclusive program, Grid Dynamics enables its clients to accelerate time to value on cloud transformation programs-freeing up investment for more advanced & disruptive digital transformation projects with Grid Dynamics.

08:47 EDT Athersys continues to explore options, expects to file for bankruptcy - Athersys intends to continue exploring available strategic options. However, in the event Athersys is unable in the near-term to enter into a strategic transaction or obtain adequate financing, it expects to have to file for protection under the bankruptcy laws to allow the company to conduct an orderly wind down of operations. In the interim, the company is streamlining its operations to preserve its capital and cash resources.

08:46 EDT Athersys announces DSMB analysis of MASTERS-2 trial, enters MOU with Healios - Athersys announced that the independent data safety monitoring board, or DSMB, has completed a pre-planned interim analysis of the company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the sample size required to achieve statistical significance is considerably larger, Athersys intends to conduct additional data analysis with independent statisticians. The company plans to pause enrollment of new patients while this analysis is being conducted. Separately, Athersys announces that it has entered into a Memorandum of Understanding, or MOU, granting Healios global rights to develop and commercialize MultiStem for the treatment of acute respiratory distress syndrome, or ARDS. Under the terms of the MOU, Athersys will receive between $1.5M and $4.5M in near term payments with up to $150M in potential development and sales milestones and additional royalties. Athersys also expects to receive revenue from the sale of existing clinical doses of MultiStem, which were manufactured in accordance with its 3D bioreactor process that earlier this year received approval from Japan's Pharmaceuticals and Medical Devices Agency, for Healios to use in its Phase 3 clinical trial in ARDS.

08:42 EDT SharpLink Gaming's LeagueSafe collects over $31.5M in entry fees for NFL season - SharpLink Gaming announced that the Company's LeagueSafe fantasy sports league management platform, acquired as part of the merger with SportsHub Games Network in December 2022, reported that it has collected more than $31.5 million in total entry fees from over 56,000 private fantasy football leagues for the 2023/2024 NFL season - up 22% when compared to the 2022/2023 NFL season. In addition, the total number of individual payments processed on the platform was 574,043, a 29% increase over the 2022/2023 NFL season.

08:41 EDT Imax will not proceed with Imax China privatization - Imax confirmed that the company's proposal to acquire Imax China's outstanding 96.3 million shares will not proceed following a vote by Imax China shareholders. At the Extraordinary General Meeting of Imax China shareholders held October 9, 70% of the shares voted were in favor of the proposed transaction; however, votes against exceeded the 10% threshold required by Hong Kong law to defeat a privatization transaction. In total, approximately 61% of the total disinterested shares of IMAX China common stock were voted. Imax China is a Hong Kong-listed subsidiary established by Imax to oversee its business in Greater China.

08:40 EDT Alliance Entertainment announces 597 new employee shareholders - Alliance Entertainment announced 100% vestment of equity grants to 597 employees under its 2023 Omnibus Equity Incentive Plan, establishing an employee-owned company. On June 15, 2023, Alliance Entertainment issued an aggregate of 468,400 shares of Class A Common Stock into a reserve for unvested restricted shares pursuant to the Company's 2023 Omnibus Equity Incentive Plan. All employees hired on or before February 13, 2023, were granted Restricted Stock Awards and all of the shares granted to 597 employees were fully vested on October 4, 2023. Bruce Ogilvie, Chairman of Alliance Entertainment, commented, "Our Equity Incentive Plan represents our goal to unite all employees around our mission by offering a share in the Company's future. As an employee-owned company we believe we can further improve business performance and reward employees for their hard work and commitment. The plan is a part of our Environmental, Social & Governance initiatives, including creating and sustaining a safe, diverse and inclusive working environment for our employees. We were excited to celebrate this milestone along with 597 truly deserving employees for all that they do to drive value for our customers, and their efforts to build Alliance's leadership as the premier distributor of music, movies, video games, electronics, arcades, toys and collectibles."

08:37 EDT MeridianLink and Blend announces integration, no terms - Blend announced an integration with MeridianLink , a provider of modern software platforms for financial institutions and consumer reporting agencies. With this integration, lenders using MeridianLink Consumer will have the ability to leverage Blend's unified platform and consumer banking origination software for a fast onboarding and application process for banking, credit card, and loan products. This new integration adds to the partnership landscape, with Blend already integrating with MeridianLink Mortgage. "Our Marketplace unites a multitude of industry-leading solutions with the MeridianLink One platform to deliver exceptional consumer experiences and streamline contemporary lending processes."

08:37 EDT Planet Green Holdings unit partners with MetaMind AI Limited - Planet Green Holdings announced that its subsidiary, Allinyson Ltd., has achieved an one-year-term groundbreaking strategic partnership with MetaMind AI Limited, aiming to revolutionize the landscape of artificial intelligence technology services. This collaboration, established through a Cooperation Agreement, is set to drive innovation, and propel both companies into the forefront of the AI industry. Under the Cooperation Agreement, Allinyson and MetaMind mutually acknowledge each other as strategic partners and grant permission to establish partner logo links or text links on their respective websites. Both parties also authorize their partner to repost relevant information from the other party's website on their sites, with proper attribution. In addition, Allinyson and MetaMind collaborate to jointly promote and endorse each other's brands both online and offline, including exhibitions, seminars, forums, and brochures. MetaMind will also provide application programming interface and technical support tailored to meet Allinyson's specific business requirements.

08:36 EDT Inozyme highlights inclusion of GACI in Genomics England's Generation Study - Inozyme Pharma highlighted the inclusion of Generalized Arterial Calcification of Infancy, which is caused by mutations in the ENPP1 or ABCC6 genes, in the Genomic England's Generation Study. This research initiative, embedded within the UK's National Health Service, was developed to advance early detection and treatment of rare genetic conditions, with the goal of setting a new standard for newborn screening programs. "We commend Genomics England for recognizing the crucial importance of early detection of GACI as we advance INZ-701 into clinical trials in infants. Including ENPP1 and ABCC6 in the initial list of genes selected for this groundbreaking study represents the hard work and dedication of the advocates, families, and healthcare professionals who work tirelessly for those living with this disease," said Catherine Nester, R.N., Inozyme's senior vice president of healthcare professionals and patient engagement. "The Generation Study has the potential to make a significant impact on the creation of more comprehensive newborn screening programs that save lives by empowering families to find appropriate care for their babies as quickly as possible." The Generation Study is scheduled to begin in late 2023, with the goal of sequencing the genomes of more than 100,000 infants and paving the way for potential widespread implementation of whole-genome sequencing in newborn screening. Genomics England collaborated with NHS experts as well as scientists, healthcare professionals, and people living with rare conditions to select 223 individual conditions for its current screening program.

08:36 EDT Norwegian Cruise Line appoints Cil to board of directors - Norwegian Cruise Line (NCLH) announced the appointment of Jose Cil to its Board of Directors as a new independent director, effective October 6, 2023. With Cil's appointment, the Board has expanded from eight to nine members, seven of whom are independent. Cil will serve as a member of the Company's Audit Committee. Cil served as Chief Executive Officer of Restaurant Brands International (QSR) from January 2019 to March 2023.

08:35 EDT ZimVie announces recent launch of Biotivity A/C Plus Membrane - ZimVie announced the recent launch of the Biotivity A/C Plus Membrane, a growth factor rich membrane used for site coverage and protection from the oral environment in a variety of dental applications. The membrane is now available in the United States. "We remain focused on bringing new products to market to meet customer needs and ensure their teams have the best solutions at their disposal," said Indraneel Kanaglekar, SVP and President of ZimVie Dental. "Biotivity's triple-layer structure is thicker than conventional A/C membranes and may contribute to enhanced conformability and growth factor content."

08:34 EDT Ballard Power announces orders for over 170 hydrogen fuel cell engines - Ballard Power Systems announced multiple purchase orders totaling 177 hydrogen fuel cell engines from long-standing customer Solaris Bus & Coach sp. z o.o., a European bus manufacturer deploying hydrogen-powered city buses across the continent. Ballard expects limited initial deliveries of the 177 fuel cell engines in 2023, with the remainder to ship from 2024 through 2026.

08:33 EDT SRM Entertainment extends multi-year SMURFS license agreement - SRM Entertainment signed an agreement to extend the Smurfs multi-year licensing agreement with LAFIG Belgium for use of the Smurfs brand name and characters to be featured on SRM's patented Sip With Me line of children's hydration drinkware and table-top products through December 2025. SRM Entertainment's patented Sip with Me children's cups which feature Smurfs franchise characters will be sold online and at retail stores throughout the country. Through the license agreement, SRM developed a line of patented Sip with Me double drinking straw tumblers. The Sip with Me Smurf products are expected to launch at retailers prior to the all-new Smurfs film scheduled to hit theaters in February 2025.

08:32 EDT Post Holdings to acquire assets of Perfection Pet Foods for $235M - Post announced it has agreed to acquire the assets of Perfection Pet Foods for $235 million. Perfection is a leading manufacturer and packager of private label and co-manufactured pet food and baked treat products. The acquisition includes two manufacturing facilities in Visalia, California, which will provide Post with additional manufacturing capacity to insource a portion of its current pet food business and an entry point into the private label and co-manufacturing pet food category. Upon closing of the acquisition, the financial results of Perfection are expected to be reported in the Post Consumer Brands segment. Inclusive of stand-up costs, Post management expects Perfection to contribute approximately $25M of Adjusted EBITDA in the next 12 months following the close of the acquisition. Additionally, Post expects the acquisition to result in a tax benefit to Post with a net present value of approximately $20 million and reduce future capital expenditures previously earmarked for capacity expansion. The acquisition is expected to be completed late in the fourth calendar quarter of 2023, Post's first quarter of fiscal year 2024, subject to customary closing conditions.

08:31 EDT Splash Beverage enters new agreement with Horizon Retailers Association - Splash Beverage Group has entered into a new agreement with Horizon Retailers Association. Based in Atlanta, GA, HRA is one of the South's fastest growing convenience store retail associations, representing more than 2,500 retailers and 20 major vendors in the Southeast US.

08:28 EDT Biotricity announces patent filing for Bioheart device - Biotricity announced its patent filing for the company's Bioheart device. Bioheart, regarded as one of the most innovative wearable heart monitoring solutions and recognized as one of TIME Magazine's Best Inventions of 2022 stands as a "game changer" in the industries of personal heart and remote lifestyle monitoring. This patent safeguards Bioheart's exclusive 3-view dry-contact technology, advanced sensor system, unique design, and compact form factor - a combination that's never been seen in the consumer market. This patent application reaffirms Biotricity's commitment to enhancing its Intellectual Property portfolio, protecting its innovations while strengthening its position as a leader in personal lifestyle and healthcare innovation. Dr. Waqaas Al-Siddiq, CEO of Biotricity, commented on the patent filing, stating, "It is with great pride that we announce the filing of our second Biotricity patent in just a month. The Bioheart patent filing reflects our focused commitment to advancing our broader strategy to continuously strengthen our IP, trade secrets, and FDA 510(k) portfolios. This not only helps solidify our leadership in the industry but also ensures that our competitive advantages remain at the forefront of the market."

08:27 EDT Intrusion awarded $5M shield agreement with large telecommunications provider - Intrusion announced that it has been awarded a $5 million agreement with a large telecommunications provider to provide Intrusion Shield support for its data centers. The award includes a phased rollout of Intrusion Shield beginning in the fourth quarter of 2023 and builds on a successful pilot that began in the first quarter of 2023. The terms of the five-year award allow for further expansion of the use of Intrusion Shield, with the possibility of generating additional revenue after the completion of the initial set of projects. During the third quarter of 2023, Intrusion also booked four other new contracts, which are also expected to grow over time. 'We are excited to announce this multi-year agreement, which utilizes our capabilities in protecting critical infrastructure from cyber attackers,' said Tony Scott, CEO of Intrusion. 'We've seen an increase in the targeting of data centers for numerous businesses around the world, and this award is evidence of the effectiveness and capabilities of Intrusion Shield at scale. With this award and the other four new contracts across diverse industries we signed in the third quarter, we see signs that our go-to-market strategy with partners is working.' Intrusion will provide further information about the transaction with the large telecommunications provider after final implementation details have been agreed upon, and a public announcement ceremony has been scheduled.

08:25 EDT Renovaro BioSciences appoints Boeren, Hendriks as Independent Directors - Renovaro Biosciences (RENB) announces the appointment of Leni Boeren and Ruud Hendriks as Independent Directors. Renovaro recently announced a definitive agreement to combine with the advanced AI Company GEDi Cube Intl Ltd. GEDiCube intends to rebrand as Renovaro AI, as announced on September 29, 2023. Both Leni and Ruud bring extensive, high-level experience in finance and business. Boeren currently holds non-executive positions with NIBC Bank, Air France-KLM (AFLYY), Ohpen, and Mollie. Hendriks's current positions include being a senior adviser to Pictet Group, a leading independent investment firm, and Van Lanschot Kempen N.V., an independent wealth manager.

08:25 EDT Meta Materials appoints Philippe Morali to board of directors - Meta Materials has appointed Mr. Philippe Morali to its Board of Directors. In his last position, Mr. Morali was CFO at eSilicon, an ASIC and IP supplier that was acquired by Inphi Corporation and Synopsys.

08:23 EDT Perspective Therapeutics' VMT-a-NET protocols presented at NANETS sympsium - Perspective Therapeutics announced that two upcoming investigator-initiated trials were presented at the North American Neuroendocrine Tumor Society, NANETS, 2023 Symposium in Montreal, Canada, which was held October 4-6, 2023. Presentation One: Phase 1 Trial of Pb-212-VMT-alpha-NET in Select Metastatic or Inoperable Somatostatin Receptor Positive Tumors. Summary: This presentation detailed the planned protocol for the IIT Phase 1 trial of Pb-212-VMT-alpha-NET in patients with metastatic or inoperable somatostatin receptors positive tumors to investigate if this new treatment can improve management of patients naive to prior radioligand therapy. The study is an open-label, single arm, single-center, phase 1 trial evaluating the safety, tolerability, and pharmacokinetic properties of the alpha-emitting, systemic radioligand therapy agent Pb-212-VMT-alpha-NET in five different SSTR+ tumors: gastrointestinal neuroendocrine tumors, pheochromocytoma and paraganglioma, small cell lung cancer, renal cell carcinoma, and head and neck. Enrollment for this study is expected to commence in the first quarter of 2024. Presentation Two: Phase 1/2 Trial of Pb-212-VMT-alpha-NET in GI Neuroendocrine Tumors and Pheochromocytoma/Paraganglioma Previously Treated with Radioligand Therapy. Summary: This presentation detailed the planned protocol for the IIT Phase 1/2 trial designed to determine if such a new treatment can improve management of patients who have progressed on beta-emitting radioligand therapy. This study is an open-label, single arm, single-center, Phase 1/2 study evaluating the safety, tolerability, and pharmacokinetic properties of the alpha-emitting, systemic radioligand therapy agent Pb-212-VMT-alpha-NET in somatostatin receptors metastatic GI neuroendocrine tumors and pheochromocytoma/paraganglioma tumors. Enrollment for this study is expected to commence in the first quarter of 2024.

08:21 EDT Super League Enterprise participates in Advertising Week NY 2023 - Super League announced its participation in the esteemed Advertising Week NY 2023. The company will be prominently represented on two dynamic panel presentations. Ann Hand, Super League's Chair and CEO, will join a thought-provoking discussion on what is possible for brands when activating on innovative new platforms in a panel titled Brand Alchemy: Turning Your IP Into Content Gold. Joining Ann are esteemed colleagues Julia Fitzgerald, CMO of Build-A-Bear and Kristin Patrick, CMO of Claire's. Together, with moderator Jared Scott, Chief Marketing and Operations Officer for The Revival House, they will explore the art of storytelling in branding, discussing how to harness the power of iconic IP, innovate new IP beyond traditional brick and mortar, and how captivating content can amplify brand value. In a separate panel, Matt Edelman, President and Chief Commercial Officer of Super League, will share learnings from Super League's recent partnership with the internationally-renowned musical Hamilton on the immersive experience Hamilton Simulator on the panel called Why Hamilton Created an Immersive Experience on Roblox and How It's Performing. Matt, alongside Maggie Brohn, Chief Operating Officer for Adventureland and Executive Producer of Hamilton and moderator Sam Ewen, Head of CoinDesk Studios will discuss the significance of this major collaboration and its current progress.

08:19 EDT Trinity Biotech welcomes decision of High Court of Kenya to strike out lawsuit - Trinity Biotech welcomes the recent decision by the High Court of Kenya. The court has struck out both the interim application and the entire lawsuit filed by Gamma Zenith Kenya Limited against Trinity Biotech, Radiance Pharmaceutical, the Kenyan Ministry of Health, and the Kenyan Attorney General, that sought to prevent the Kenyan Ministry of Health's procurement of TrinScreen HIV test kits. The High Court also discharged the interim orders that previously placed temporary restrictions on the procurement of TrinScreen HIV tests. This court ruling marks a positive development for both public health in Kenya and Trinity Biotech. It signifies the removal of the legal barriers that had hindered the sale of TrinScreen HIV test kits to the Kenyan Ministry of Health. Consequently, Trinity Biotech is now able to proceed with supplying TrinScreen HIV in Kenya. Trinity Biotech expects to imminently receive TrinScreen HIV orders for the new Kenyan HIV rapid testing algorithm. A separate legal case against the Kenyan Ministry of Health and others, which challenged the new HIV rapid testing algorithm, was scheduled for a ruling on October 5, 2023. However, the ruling was not delivered as the trial judge was not available. The ruling will be delivered on notice, meaning that the court will issue its decision at a later date.

08:16 EDT Canacol Energy says gas sales averaged 161 MMscfpd in September - Realized contractual natural gas sales were 161 million standard cubic feet per day for September 2023. Average realized contractual natural gas sales for the month of October 2023 to date are 162 MMscfpd, with current contractual natural gas sales as of October 9, 2023 being 180 MMscfpd of gas. Realized contractual natural gas sales for the third quarter of 2023 averaged 178 MMscfpd, down slightly from the 185 MMscfpd and 186 MMscfpd reported in the second and first quarters respectively. Preliminary adjusted EBITDAX for the third quarter is estimated to be $61 million and in line with the $60.7 million and $60.9 million reported in the second and first quarters respectively. Commencing the second week of August 2023 the Corporation experienced unusual and unexpected production capacity restrictions at some of its gas fields as a result of issues at the Jobo gas treatment facility as well as certain of its producing wells. As a result of the foregoing the Corporation has had to restrict gas deliveries under certain supply contracts dedicated to supplying non-essential gas demand, all in accordance with applicable Colombian regulations and in consultation with the relevant authorities. The Corporation is presently working on remediating this short-term disruption and expects to have production back to normal levels shortly. The Corporation anticipates that it will be able to make up lost sales volumes by year end and meet its average production and financial targets and therefore does not expect this situation to have a material impact on its operations and results. The Corporation completed the drilling of the Aguas Vivas 4 development well on September 16, 2023, encountering 357 feet true vertical depth ("ft TVD") of net gas pay within the main Cienaga de Oro sandstone target. The well was tied into permanent production and has been on production since September 26, 2023. The Corporation completed the drilling of the Clarinete 9 development well on October 5, 2023. The well encountered 236 ft TVD of net gas pay within the CDO sandstone reservoir and is currently being cased and completed prior to tying into the permanent production facility by October 24, 2023. The Corporation completed the drilling of the Fresa 2 appraisal well targeting sandstones of the upper CDO sandstone reservoir that are productive in the offsetting Fresa 1 exploration well drilled in 2021. Fresa 2 encountered 10 ft TVD of net gas pay within the upper CDO target. The Corporation is scheduling to complete and tie in the Fresa 2 well in November 2023. The Corporation is currently drilling the Pandereta 9 and Nelson 15 development wells, both targeting infill drilling locations within the respective producing fields. The Corporation plans to have both wells tied in and on production prior to the end of October 2023.

08:15 EDT Nuwellis provides regulatory update on SeaStar Medical's SCD-PED - Nuwellis announced that its distribution partner, SeaStar Medical, received correspondence from the U.S. Food and Drug Administration's, FDA, Center for Biologics Evaluation and Research, CBER, indicating that the Agency considers SeaStar's Selective Cytopheretic Device, SCD, Pediatric, SCD-PED, to be approvable under a Humanitarian Device Exemption, HDE, for use in children weighing 10 kilograms or more with acute kidney injury, AKI, and sepsis or a septic condition requiring continuous kidney replacement therapy, CKRT, in the hospital intensive care unit, ICU. The correspondence indicates that an Approvable Letter is expected to be issued within a month. The Approvable Letter will outline conditions, including language for safety, probable benefit and labeling for intended use, which will be required for formal marketing approval. "This regulatory update is an important milestone for our partner, SeaStar, who intends to follow the regulatory path laid out by the FDA for marketing approval to commercialize SCD for the pediatric indication by the end of 2023," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "Nuwellis' pediatric team is excited to finally bring this lifesaving therapy to serve the needs of its growing network in the pediatric clinical community."

08:13 EDT OrthoPediatrics announces limited release of DF2 Brace - OrthoPediatrics announced the limited release of the DF2 Brace as part of its expansion in the non-surgical business for treating kids with musculoskeletal injuries. The DF2 Brace is intended for femur fracture fixation in pediatric patients from approximately 6 months to 5 years of age instead of spica cast by providing immobilization of the femur, knee, and hip. Joe Hauser, President of Trauma and Deformity Correction at OrthoPediatrics, added, "This is the first product launch for the OrthoPediatrics Specialty Bracing group and will significantly improve the care of kids with femur fractures. The ability to eliminate anesthesia and complications associated with spica casts, all while reducing the overall cost of care is a significant advancement in pediatric orthopedics for patients, their families and surgeons."

08:11 EDT Genasys announces $1M U.S. Army CROWS-AHD prototype contract - Genasys announced a $1M contract with the U.S. Army to design and build the first CROWS-AHD prototypes. This effort is a continuation of the CROWS-AHD Technical Feasibility Study that Genasys completed earlier this year. "Adding LRAD 450XLs to CROWS is a natural extension of our successful U.S. Army AHD Program of Record," said Richard S. Danforth, Chief Executive Officer of Genasys Inc. "This innovative merging of two existing technologies will improve operational effectiveness and reduce the incidence of non-combatant casualties." The feasibility study is being conducted by the Program Executive Office Soldier, located in Ft. Belvoir, VA. The fiscal year 2024 defense appropriations bill is expected to provide initial funding for the CROWS-AHD program and Congress has expressed an interest in accelerating the fielding of this capability. The current contract funds the effort through May 2024.

08:11 EDT MAIA Biotechnology says THIO showed highly potent anticancer activity in gliomas - MAIA Biotechnology announced that its lead asset THIO showed highly potent anticancer activity in gliomas, an aggressive type of brain tumor that originates from glial cells. THIO's novel dual mechanism of action - direct telomere targeting and immune system activation, has previously demonstrated similar efficacy in multiple types of telomerase-active tumors. THIO was evaluated in various in vitro and in vivo models of gliomas. The results demonstrate the promising therapeutic role of THIO for the treatment of primary and temozolomide-resistant recurrent gliomas through specific telomerase-mediated induction of telomeric DNA damage in glioma cells.

08:11 EDT Ambi Robotics, Pitney Bowes team to automate 'Middle-Mile Sorting' - Ambi Robotics and Pitney Bowes announced the successful deployment of the new AmbiSort B-Series modular parcel induction and sorting solution for middle-mile operations. This collaboration between two industry leaders advances ecommerce and logistics operations through cutting-edge automation and emerging technologies."The successful deployment of the AmbiSort B-Series is a result of strategic and collaborative innovation between the two companies," said Jim Liefer, CEO of Ambi Robotics. "Pitney Bowes is pioneering the future of smart logistics and has been at the forefront of transforming warehouse work to align with the demands of constant ecommerce. This partnership serves as a model of such collaborative innovation and sets a high bar for future supply chain modernization."

08:09 EDT PrairieSky Royalty appoints Dan Bertram as CCO - PrairieSky Royalty announced the appointment of Dan Bertram as Vice-President, Business Development and Chief Commercial Officer. Bertram was most recently Senior Vice President and Chief Strategy Officer at Superior Plus Corp., a leading North American energy distributor.

08:07 EDT Curaleaf applies to list subordinate voting shares on Toronto Stock Exchange - Curaleaf Holdings announced that it has filed its application to list the company's subordinate voting shares on the Toronto Stock Exchange. As previously announced, the company completed a marketed offering of subordinate voting shares on October 3, 2023 in order to satisfy a condition required for a potential listing on the TSX.

08:06 EDT Inovio receives positive FDA feedback for accelerated Phase 1/2 INO-3107 trial - Inovio has received feedback from the FDA that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support Inovio's submission of a BLA for review under the FDA's accelerated approval program. The FDA also advised that the company's previously planned Phase 3 randomized, placebo-controlled trial would not be required to support this submission. Inovio will be required to initiate a confirmatory trial prior to BLA submission for accelerated approval and satisfy all other FDA filing requirements. The design of the confirmatory trial has not yet been finalized. If approved, INO-3107 would be the first DNA medicine in the U.S. and the first Inovio candidate to receive regulatory approval. Treatment with INO-3107 generated a strong immune response in the trial, inducing activated CD4 T cells and activated CD8 T cells with lytic potential. T-cell responses were also observed at Week 52, indicating a persistent cellular memory response. INO-3107 was well tolerated by participants in the trial, resulting in mostly low-grade treatment-emergent adverse effects such as injection site pain and fatigue.

08:06 EDT Axcelis ships Purion Dragon to research center in Europe - Axcelis Technologies announced a shipment of the Purion Dragon high current implanter to a world-leading research and innovation center in nanoelectronics and digital technologies located in Europe. The system will be used in technology development for advanced logic devices. The system shipped in the third quarter of 2023.

08:05 EDT DLH Holdings appoints David Affeldt as strategic advisor - DLH Holdings announced that David Affeldt has been appointed to a strategic advisory role for the Company. In this position, Mr. Affeldt will provide insight to executive management and the Board of Directors on a broad range of information technology solutions, including client services, organic growth, and corporate development. Affeldt is the former President and CEO of Grove Resource Solutions, which was acquired by DLH in December 2022.

08:04 EDT Nogin announces exit from product sales business - Nogin announced final agreements with various parties that complete the transition of Nogin exiting its product business. After this quarter, there will be no product sales reported from these businesses, which Nogin had previously indicated were targeted for transition. In addition, each of these relationships is now converted into a CaaS structure whereby Nogin contributes its ecommerce expertise while the partners we've allied ourselves with contribute their considerable product sourcing, design and inventory management expertise. These transactions will drive favorable impacts to our income statement and balance sheet and enable these customer relationships and businesses to grow substantially in the near term. Jonathan Huberman, Nogin's President, Chief Executive Officer and Chairman, said: "As we have consistently communicated, our product related business was not generating the financial results consistent with our profitability targets nor our business strategy. During our Q2 results call we noted two clients in this category, which, as of this week, we've consummated a transition plan with various parties for each. Consequently, we are moving into the final quarter of the year with a business that is 100% focused on our CaaS offering, and we're on track to report full year results that reflect material reductions in SG&A and other efficiencies."

08:03 EDT Clarus acquires TRED Outdoors from Venlo Holdings - Clarus announced it has acquired Australian-based TRED Outdoors Pty from Venlo Holdings. TRED is a fast-growing, outdoor adventure brand producing best-in-class innovative products across the following segments: Offroad, 4x4 automotive touring, camping and caravans. The transaction includes a combination of cash, stock and future consideration based on TRED's performance. Warren Kanders, Executive Chairman of Clarus, added, "This transaction highlights our continued focus on identifying sought-after brands within the Adventure segment that both enhance our offering to existing retail customers and expand our reach into new and larger channels. The acquisition is expected to be immediately accretive to earnings." Terms of the transaction were not disclosed.

08:03 EDT Sportradar selected to power Taiwan Sports Lottery - Sportradar has been selected as the official technology and services solution provider by the Taiwan Sports Lottery, following an international tender process. Based on the breadth of services included, the structure and longevity of the industry-first agreement, Sportradar is set to transform the sports betting experience in Taiwan as part of the consortium that will operate the Taiwan Sports Lottery from 2024 through 2033. Being appointed as part of the consortium formed by ADATA Technology as the license holder, Taiwan Sports Lottery Company Ltd as the operator and China Trust Bank, further strengthens Sportradar's industry position in the Asia Pacific region. The consortium was awarded the third Sports Lottery License issued by the Taiwan Government's Sports Administration in December 2022. ORAKO, the Company's end-to-end sportsbook and player account management solution, will be fully implemented across more than 2,600 retail outlets in Taiwan as well as across web and mobile channels as it is designed to scale for omnichannel use. Sportradar's technology will power the Lottery with ORAKO Sports Betting and Player Management platform, Managed Trading Services, Pre-match and Live data and odds, Audiovisual streaming, Marketing services and other Sportradar ORAKO solution integrated services. The solution includes the delivery of the required equipment at retail stores including customized lottery terminals and printers, and digital multimedia displays to provide live sports and betting information. As part of the agreement, Sportradar also established a local team in Taipei to provide operational support and expertise alongside TSLC's team members on the ground.

07:58 EDT Gol Linhas reports preliminary traffic data for September 2023 - Gol Linhas reported preliminary air traffic figures for September 2023 vs. the same period in 2022. GOL's total supply- ASK - increased 4.7%. Total seats increased 12.1% and the number of departures increased by 11.2%. GOL's total demand - RPK - increased by 6.7%. GOL's domestic supply increased 6.1% and demand increased by 8.4%. GOL's domestic load factor was 83.4%. The volume of departures increased by 11.4% and seats increased by 12.3%. GOL's international supply was 296 million and RPK was 243 million. Cargo volume was up 81.7%, reaching 10,2 thousand tons in September.

07:50 EDT Ameresco completes GBP 4M multi-phase infrastructure redevelopment project - Ameresco announced that it has completed a GBP 4M multi-phase infrastructure redevelopment project with the Barnsley Metropolitan Borough Council. The project was completed in two key phases, the first phase focused on replacing existing coal-fired boilers with a new combined heat and power, or CHP, and gas-fired system, while the second phase prioritized the decarbonization of heat.

07:40 EDT Kamada continues to conduct business operations in Israel - Kamada announced that while circumstances in Israel are evolving, the Company continues to conduct its business operations in Israel with no effect on business continuity, and its global supply of products is not expected to be interrupted. Kamada will provide further updates if and when material events so warrant. "We, at Kamada, are profoundly horrified by the devastating terrorist attacks in Israel during recent days. Our deepest condolences, thoughts and prayers are with those impacted by these terrifying events," said Amir London, CEO. "We are focused on the well-being of our Israeli employees, providing them with support required. While events in Israel are evolving, our global activity and the supply of our products are expected to continue as planned. We are monitoring the situation closely and will provide updates if and when needed. We thank all our partners, investors and customers who have reached out during recent days to express their heartfelt support."

07:36 EDT Bombardier to display Challenger, Global aircraft at NBAA-BACE 2023 - Bombardier announced its lineup of Challenger and Global aircraft on display at static during NBAA-BACE in Las Vegas Oct. 17-19, highlighting the uncompromising attributes of its aircraft family. Shining brightly at NBAA-BACE this year will be the immaculate Global 7500, Global 6500, Challenger 3500, and Challenger 650 business jets. A Challenger 300 Certified Pre-Owned aircraft will also be on display, marking the first time a sought-after CPO aircraft will be showcased to the public in North America. The company said, "Bombardier's impressive lineup of long- and ultra-long-range aircraft aptly highlights the outstanding characteristics that sets it apart from the competition, trumpeting the fleets' unsurpassed performance, outstanding technological advancements, cutting-edge sustainability attributes, and luxurious, exceptional cabins for maximum productivity and comfort."

07:34 EDT Amesite launches 12 courses with Michigan Works! Southeast - Amesite announced the expansion of its partnership with Michigan Works! Southeast. In this collaboration, 12 new courses will be launched in 2023, focusing on training in artificial intelligence technologies and its applications in the modern workplace. These courses will be made available on MWSE's proprietary Learning Community Environment powered by Amesite. The new courses delve into the transformative wave of Industry 4.0, offering a deep dive into how digitalization is reshaping the workplace. With dedicated modules on the underpinnings of internet technology and the challenges posed by AI in job retention, the curriculum provides essential insights for today's workforce. Notably, several courses spotlight the innovative use of ChatGPT, teaching students to craft compelling resumes, cover letters, and follow-up emails, and even optimize their online job search and interview strategies. Additionally, there's a strong emphasis on leveraging AI for business growth and ensuring robust data safety in an ever-connected world.

07:32 EDT BridgeBio announces proof-of-concept Phase 2b data on encaleret - BridgeBio Pharma announced that the proof-of-concept Phase 2b data evaluating the effects of orally-administered encaleret on mineral homeostasis in patients with ADH1 were published in the New England Journal of Medicine in partnership with the National Institutes of Health. As part of the Phase 2b study, participants completed one or two 5-day inpatient dose-ranging periods, followed by a 24-week outpatient period. Encaleret was administered twice daily with doses adjusted to achieve normal albumin-corrected blood calcium levels and participants stopped taking calcium and vitamin D supplements, the standard of care for ADH1. The results showed that: Encaleret corrected hypocalcemia and reduced hypercalciuria within a few days of treatment initiation with sustained effect during the 24-week outpatient period; As expected with elevated PTH levels, levels of bone turnover markers increased during the outpatient period, with levels in nine of 13 participants remaining normal. Long-term study will continue to assess skeletal effects; Kidney function and preexisting renal calcifications did not worsen and will continue to be monitored in longer-term studies. No serious adverse events were reported with encaleret. Treatment-related adverse events were limited to infrequent mild, transient, asymptomatic hypophosphatemia, or hypercalcemia that resolved either spontaneously or with dose adjustment; No treatment discontinuations or study withdrawals occurred

07:31 EDT Zevra Therapeutics appoints McFarlane as President, CEO, dierctor - Zevra Therapeutics announced that Neil McFarlane has been named President and Chief Executive Officer of Zevra and appointed to the Board of Directors, effective October 10, 2023. Neil succeeds Christal M.M. Mickle who has been serving as interim CEO and President since June 2023, and who will continue serving in her role as Chief Development Officer. Concurrently, the Company announced the effectiveness of Joseph Saluri's previously announced retirement from the Board of Directors. Saluri's retirement is in accordance with the plan announced by the Company on May 8, 2023. McFarlane most recently served as the Chief Executive Officer and a member of the Board of Directors of Adamas Pharmaceuticals, Inc. until November 2021

07:19 EDT ThinkSono joins Butterfly Garden for ThinkSono AI on Imaging Platform - ThinkSono has joined Butterfly Garden, an artificial intelligence Marketplace launched by Butterfly Network (BFLY). Under this partnership, ThinkSono plans to build ThinkSono AI training solutions and ThinkSono Guidance, a deep vein thrombosis clinical solution for use with Butterfly's single-probe, whole-body handheld ultrasound system, subject to applicable approvals and authorizations. ThinkSono and Butterfly aim to enable healthcare practitioners to learn several key point-of-care ultrasound scans, including the detection of deep vein thrombosis.

07:15 EDT Aura Minerals reports Q3 production 64,875 GEO - Total production in GEO increased by 34% in Q3 2023 compared to Q2 2023, due to the commencement of commercial production in Almas mine, higher production at the Aranzazu, San Andres and EPP mines. Compared to Q3 2022, production increased 12%. At Aranzazu, production was 27,933 GEO in line with the Company's expectations. Production was 11% higher compared to Q2 2023, due higher tonnage and higher head grades. Compared to Q3 2022, production also increased by 7%. At EPP, production was 11,185 GEO, 62% higher in Q3 2023 than in Q2 2023. As expected, the production increase in EPP was attributable to the high-grade zone in Ernesto and a reduction in the use of existing stockpiles. The Company will continue mining in the higher-grade zone in Ernesto during the last quarter of the year and expects a robust fourth quarter production, in a trend similar to the one observed in 2022. Compared to Q3 2022, production decreased 38%. At San Andres, production was 17,543 GEO for the quarter, representing a 7% increase compared to the previous quarter. This represents a third quarterly increase in production in a row. The quarter's production was enhanced by operational efficiency with the upgrade in the stacking system with the installation of new grasshoppers, boosting productivity. Compared to Q3 2022, production at San Andres increased by 25%. At Almas, production was 8,214 GEO considering only two months of production. Almas commenced commercial production this quarter, and the results have exceeded market benchmarks. Furthermore, upgrades in infrastructure are underway to increase the plant processing capacity for the upcoming quarters. Rodrigo Barbosa, Aura's President and CEO commented, "In this quarter, we experienced a significant rise in production volumes in all our operations. Also, a standout accomplishment this quarter was Almas's ramp-up, which exceeded industry benchmarks. As our operations thrived, we finalized and released a highly accretive Feasibility Study, secured funding and commenced construction at Borborema. We, at Aura team, are focused and building a solid track record in order to achieve our 450,000 Oz annualized by the end of 2025."

07:14 EDT SMX secures majority stake in True Gold Consortium - SMX has signed an agreement with True Gold Consortium to acquire an additional 7.5% equity stake, thereby increasing the company's common share holdings in privately held TrueGold to 51.9%. In exchange for the additional 7.5% equity, the agreement stipulates, among other things, a waiver of outstanding payables amounting to AU$475K - approximately $307K - from TrueGold to SMX as of June 30, 2023 and SMX licensing additional intellectual property to TrueGold. The valuation underpinning this transaction is based on a previous assessment conducted in October 2021, which appraised TrueGold's worth between $78.5M and $90M, using the mean value of $84.3M. SMX and TrueGold will commission an independent third-party appraiser to ascertain an updated valuation of TrueGold by October 31. TrueGold will have the right, within 12 months, to repurchase the additional interest from Security Matters for a purchase price based on such fair value.

07:13 EDT Farmland Partners announces several asset dispositions, farm acquisition - Farmland Partners announced that it finalized numerous transactions over the third quarter of 2023, including the disposition of more than 13,500 acres in California, Colorado, Georgia, Illinois, Louisiana, and Kansas, and the purchase of a 1,523-acre farm in Morehouse Parish, Louisiana. The sales cumulatively totaled more than $70M and represented a gain on sale of approximately 17%. The acquisition in Louisiana is nearby other FPI farmland and primarily produces corn and soybeans. It was purchased for approximately $11M.

07:11 EDT PowerFleet and MiX Telematics announce business combination - PowerFleet (PWFL) and MiX Telematics (MIXT) have entered into a definitive agreement to form a mobile asset Internet of Things Software-as-a-Service provider. This combination will form a scaled, global entity focused on solving mission-critical business challenges including safety and risk management, compliance, sustainability, and operational efficiency. The combined business will have a total revenue of $279M, including $210M in recurring high-margin SaaS revenue and $39M of adjusted EBITDA for the twelve-month period ended June 30, 2023. The transaction is expected to close in 1Q24. Upon close, the combined business will be branded as Powerfleet, with its primary listing on Nasdaq. With a combined base of approximately 1.7 million subscribers following the transaction, the joint entity is expected to achieve significant scale. MiX shareholders will exchange 100% of their outstanding MiX ordinary shares for consideration consisting of Powerfleet common shares, payable at closing. The number of Powerfleet common shares to be issued as consideration will be based on a post-transaction ownership structure, whereby current MiX shareholders will own approximately 65%, and current Powerfleet shareholders will own approximately 35% of the combined entity immediately following the closing of the transaction. Powerfleet and MiX are positioned to secure $75M in incremental debt which the companies anticipate will be fully executed at or before close. The proceeds from the refinancing of the combined company's balance sheet will be used to redeem in full the outstanding convertible preferred stock held by affiliates of Abry Partners. Following the transaction, Steve Towe will remain CEO of Powerfleet and David Wilson will remain CFO. Stefan Joselowitz, current CEO of MiX, will be retiring. A new board of directors of Powerfleet will be formed. Michael Brodsky will be Chairman. Steve Towe will be on the board. Ian Jacobs, MiX Telematics' current Chairman, will be joining the board. MiX will appoint one additional board member and further board member appointments will be made by mutual consent.

07:10 EDT Emerita Resources announce additional drilling results from IBW project - Emerita Resources announces additional drilling results from the ongoing drilling program at La Romanera Deposit, part of Emerita's wholly owned Iberian Belt West project, IBW. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. Results contained in this release are from La Romanera deposit where drilling is tracing the extension of the deposit at depth.

07:08 EDT GXO Logistics, ASOS celebrate 10th anniversary of partnership - GXO Logistics announced that it is celebrating its 10th year as a strategic supply chain partner for online fashion destination ASOS. "We're proud to have served ASOS for the past decade, providing an array of services at multiple sites in the UK and Europe," said Gavin Williams, Managing Director, U.K. & Ireland, GXO. "Over the last ten years we have handled nearly 400 million customer orders and over 270 million returns at our UK sites alone. ASOS is a true partner, sharing our commitment to supply chain excellence as well as corporate social responsibility, in particular the fantastic engagement programmes we deliver together for our on-site colleagues. We look forward to continuing our shared success, leveraging our leading teams, expertise and technologies to help ASOS excel." GXO manages inbound and outbound warehouse operations as well as returns, repairs and salvage for ASOS. The partnership began at a single facility in Barnsley, U.K., in 2013, and together the companies have since expanded their footprint in the U.K. and Europe. GXO also handles transport operations with a fleet of approximately 30 trailers.

07:07 EDT Next Hydrogen Solutions secures $7.7M agreement for project - Next Hydrogen Solutions has entered into a $7.7M agreement for a project involving a specialized nuclear application. Under the agreement, Next Hydrogen will conduct design engineering and subsequently provide the electrolyser needed (Phase 2) for the Project. A $5M purchase order has been received for Phase 1 with a follow-on order of $2.7M planned for Phase 2 with electrolyser delivery expected to occur in 2025.

07:05 EDT Nova Vision Acquisition announces additional contribution to trust account - Nova Vision Acquisition announced that Nova Pulsar Holdings Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $69,763.37, in order to extend the period of time the Company has to complete a business combination for an additional one month period, from October 10, 2023 to November 10, 2023. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the Company's units at a price of $10.00 per unit at the closing of a business combination by the Company. The purpose of the extension is to provide time for the Company to complete a business combination.

07:05 EDT Copart announces strategic investment and partnership with Purple Wave - Copart announced a new strategic investment and partnership with Purple Wave, an online offsite heavy equipment auction company. Founded in 2000, Purple Wave is a pioneer in the online equipment auction industry, facilitating the sale of construction, agriculture and fleet equipment directly from a seller's location through its no-reserve auction platform on purplewave.com.

07:03 EDT Gritstone reports inducement grants under Nasdaq listing rule - Gritstone bio announced that the Compensation Committee of the company's Board of Directors granted three employees nonqualified stock options to purchase an aggregate of 47,000 shares of its common stock with an exercise price of $2.41, which is equal to the closing price of Gritstone's common stock on October 5, 2023, the date of the grant. These stock options are part of an inducement material to the new employees becoming an employee of Gritstone, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options will vest over a four-year period, with 25% of the options vesting on the first anniversary of the employees' date of hire, and 1/48th of the options vesting monthly thereafter, subject to the employees' continued employment with Gritstone on such vesting dates. The stock options are subject to the terms and conditions of Gritstone's 2021 Employment Inducement Incentive Award Plan and the stock option agreement covering the grant.

07:02 EDT Olema Oncology expands collaboration agreement with Novartis - Olema Pharmaceuticals (OLMA) announced an amendment to the existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. (NVS) to increase the size of the ongoing Phase 1/2 clinical study testing palazestrant in combination with ribociclib to approximately 60 patients. Olema first signed a clinical collaboration and supply agreement with Novartis in July 2020, the agreement was amended and restated in January 2022, and focuses on the evaluation of the safety, tolerability and efficacy of palazestrant in combination with Novartis' proprietary cyclin-dependent kinase 4 and 6 inhibitor ribociclib and/or Novartis' proprietary phosphatidylinositol 3-kinase inhibitor alpelisib in patients with metastatic ER+ breast cancer. The amendment adds approximately 30 patients to be enrolled in the cohort expansion phase of the palazestrant clinical study in combination with ribociclib.

07:00 EDT Palantir awarded AI/ML contract by U.S. Army - Palantir announced that the Army has awarded a new contract for up to three years to provide additional capabilities in support of the Combatant Commands - COCOMs -, Armed Services, Intelligence Community, and Special Forces as they continue to test, utilize, and scale artificial intelligence - AI - and machine learning - ML - capabilities. The contract, posted to the Department of Defense contracting website last week, is worth up to $250M through 2026. Since 2018, Palantir has partnered with the Army to provide leading data integration, management, and AI model training to all of the Armed Services, COCOMs, and special operators to create a common operating picture. Building on the partnership, this new phase will further the Joint All-Domain Command and Control efforts across these forces.

06:46 EDT Ocugen's mucosal vaccine candidate selected by NIH/NIAID project for trials - Ocugen announced that the National Institute of Allergy and Infectious Diseases - NIAID -, a part of the National Institutes of Health, or NIH, will conduct a trial comparing the administration of Ocugen's mucosal vaccine candidate, OCU500, via two different mucosal routes, inhalation into the lungs and as a nasal spray. Ocugen is developing a novel anti-viral mucosal vaccine platform initially targeting COVID-19 and influenza. Earlier clinical studies to prevent COVID-19 employing a similar vector administered via inhalation demonstrated increased mucosal antibodies, systemic antibodies, and durable immune response up to one year using one fifth of the dose compared to the same vaccine given via intramuscular administration. NIAID will be conducting clinical trials to evaluate several early stage vaccine candidates. The study involving Ocugen's vaccine is designed to help answer an important question - does an inhaled COVID-19 vaccine provide greater immune response than the same vaccine administered through a nasal spray. Upon completion of the trial NIAID and Ocugen will assess the results and determine next steps for OCU500. Project NextGen is a $5B multi-government agency initiative to develop the next generation of vaccines and therapeutics to combat the spread of COVID-19. Ocugen will be responsible for providing clinical trial materials and upon completion will have full right of reference to the findings.

06:38 EDT Trimble announces FedRAMP authorized status for e-Builder - Trimble announced that e-Builder Enterprise Government Edition has received an Authorization to Operate, or ATO, based on the security assessment requirements of the Federal Risk Authorization Management Program, or FedRAMP. The FedRAMP program addresses the security of commercial cloud service providers and helps government officials manage risk in a cloud-based environment.

06:37 EDT Air Lease announces Q3 activity update - Air Lease (AL) announced an update on aircraft investments and sales activities occurring in the third quarter of 2023. As of September 30, 2023, ALC's fleet was comprised of 448 owned aircraft and 79 managed aircraft, with 351 new aircraft on order from Boeing (BA) and Airbus (EADSY) set to deliver through 2029. Aircraft Investments: Delivered eight new aircraft from ALC's order book including two Airbus A220-300s, two Airbus A321neos, one Airbus A330-900neo, two Boeing 737-8s, and one Boeing 737-9. Aircraft investments in the quarter totaled approximately $450M. Sales: Sold eight aircraft to third-party buyers. Aircraft sales proceeds for the quarter totaled approximately $350M.

06:35 EDT Oculis' OCS-01 eye drops meet primary and secondary Phase 3 endpoints in DME - Oculis presented the positive results from Stage 1 of the Phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress. Data from the Stage 1 of the DIAMOND Phase 3 program showed that the trial met primary and secondary endpoints with robust statistical significance, and achieved its objective of confirming the loading and maintenance dose to be tested in Stage 2 of the trial. The trial met its primary endpoint, showing a statistically significant improvement in Best Corrected Visual Acuity in patients treated with OCS-01versus vehicle-treated patients at Week 6, which was sustained through Week 12. For two secondary endpoints, a significantly higher percentage of patients treated with OCS-01 achieved greater than or equal to improvement in BCVA, and patients in the OCS-01 treatment arm also showed significant improvement in retinal thickness as compared to vehicle. OCS-01 was well-tolerated with no unexpected adverse events observed. If approved, OCS-01 has the potential to become the first topical eye drop for the treatment of DME and address the current treatment gap by providing a non-invasive therapeutic option. Leveraging Oculis' proprietary Optireach technology, OCS-01 is a novel topical formulation of dexamethasone developed to reach the retina via an eye drop. Diabetic Macular Edema is the leading cause of vision loss and legal blindness in patients with diabetes.

06:34 EDT Hut 8 Mining mined 111 Bitcoin in September - Hut 8 Mining mined 111 Bitcoin in September. In total, 111 Bitcoin were generated, resulting in an average production rate of approximately 3.7 Bitcoin per day. No Bitcoin were sold during the month, Total balance of Bitcoin in reserve was 9,366 on September 30 - 7,269 of which were unencumbered. Installed ASIC hashrate capacity at Alberta facilities was 2.6 EH/s at the end of the month. Hut 8 produced 42.7 BTC/EH in September.

06:17 EDT American Strategic Investment Co. responds to tender offer from Bellevue Capital - American Strategic Investment Co. has filed with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 and Letter to Stockholders dated October 10 regarding the tender offer commenced by Bellevue Capital Partners on September 27 to purchase up to 350,000 shares of the company's Class A common stock at a price of $10.25 per share. The company's board of directors has made no determination of the fairness of the Tender Offer or whether it is in the best interests of stockholders, makes no recommendation and is neutral as to whether stockholders should accept or reject the offer to tender their shares. The company urges each stockholder to make its own decision regarding the Tender Offer based on the available information. The Tender Offer will expire at 11:59 PM, NYC time, on October 26, unless extended or earlier terminated by Bellevue.

06:15 EDT Modine Manufacturing to expand production of EVantage thermal management systems - Modine announced that it will expand production of its EVantage thermal management systems product family to Europe. Beginning in 2024, Modine's facility in Pontevico, Italy, will manufacture battery thermal management and electronics cooling systems for heavy-duty, commercial, and specialty vehicle manufacturers across the continent.

06:07 EDT Honeywell announces plan to realign business segments - Honeywell announced plans to realign its business segments to three compelling megatrends: automation, the future of aviation, and energy transition. The company said this shift within the company's segments will enable Honeywell to deliver accelerated organic sales growth and inorganic capital deployment, creating greater value for shareholders. The new segmentation will take effect beginning first quarter of 2024. Effective January 1, 2024, Lucian Boldea will serve as president and CEO of the Industrial Automation segment, and Ken West will serve as president and CEO of the Energy and Sustainability Solutions segment. Both Boldea and West will report to Kapur and serve as company officers. Billal Hammoud will remain President and CEO of the renamed Building Automation segment, and Jim Currier will remain President and CEO of the renamed Aerospace Technologies segment. Kevin Dehoff will remain President and CEO of Honeywell Connected Enterprise.

06:04 EDT Haemonetics to acquire Opsens for C$2.90 per share in cash, sees accretion - Haemonetics (HAE) and OpSens (OPSSF) announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for C$2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253M at current exchange rate. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. The transaction will be affected by way of an arrangement under the Business Corporations Act. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. The transaction is expected to close by the end of January 2024. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the company's existing credit agreement, is expected to be approximately 2.1x.

05:38 EDT SMX to acquire additional 7.5% equity stake in TrueGold - SMX has signed an agreement dated with True Gold Consortium to acquire an additional 7.5% equity stake, thereby increasing the company's common share holdings in privately held TrueGold to 51.9%. This acquisition helps solidify the partnership between SMX and the other shareholders of TrueGold. This strategic transaction diversifies SMX's operations into TrueGold's pioneering ventures in Research and Development, or R&D, and revenue commercialization. SMX's software technology is powered by a Distributed Ledger blockchain, representing a transformative stride towards ensuring traceability and security across the gold value chain. In exchange for the additional 7.5% equity, the agreement stipulates, among other things, a waiver of outstanding payables amounting to $307,000 from TrueGold to SMX as of June 30 and SMX licensing additional intellectual property to TrueGold. The valuation underpinning this transaction is based on a previous assessment conducted in October 2021, which appraised TrueGold's worth between $78.5M and $90M, using the mean value of $84.3M. This past valuation was neither audited nor reviewed. Pursuant to this agreement, SMX and TrueGold will commission an independent third-party appraiser to ascertain an updated valuation of TrueGold by October 31. This forthcoming appraisal estimates a fair value of TrueGold's assets and liabilities as of the closing date. Subsequently, SMX will reflect its portion of this assessed fair value in its financial statements, and TrueGold shall have the right, within 12 months, to repurchase the additional interest from Security Matters for a purchase price based on such fair value. It is anticipated that there may be material variances between TrueGold's past valuation from October 2021 and the updated assessment.

05:24 EDT Westport completes H2 HPDI heavy transport demonstration - Westport announced the completion of a heavy transport demonstration with its H2 HPDI fuel system equipped prototype truck hauling a refrigerated trailer in Madrid, Spain. The demo marks the first of its kind in Spain, representing an important step forward in the decarbonization of heavy transport for the country.

05:11 EDT Philips announces new interoperability capabilities - Philips has announced the interoperability of Philips Capsule Medical Device Information Platform, or MDIP, with Philips Patient Information Center iX, or PIC iX, providing hospitals with a comprehensive patient overview. Philips is creating an open patient monitoring ecosystem to bring together disparate medical devices and systems on a single interface. Interoperability between MDIP and PIC iX gives clinicians a new clinical perspective that enables the capture of streaming data flowing freely from a variety of medical device manufacturers on an open, scalable, secure platform. By disseminating this information through the Patient Information Center, clinicians have a single source, comprehensive overview of a patient's condition that helps empower caregivers to make treatment recommendations confidently from anywhere throughout the hospital's digital environment.

05:04 EDT ManpowerGroup, EIT InnoEnergy partner to train and upskill 800,000 workers - The green transition will drive demand for millions of new roles in renewable energy, electrification, battery technology, hydrogen and more. ManpowerGroup and EIT InnoEnergy are committed to preparing people for these new opportunities, and announced an ambitious partnership to train and upskill 800,000 workers in the battery value chain across Europe by the end of 2025. The collaboration between ManpowerGroup and InnoEnergy's Skills Institute will provide accelerated virtual and in-person training for 70 in-demand roles including Battery Technicians, Electric Vehicle, or EV, Chargers Maintenance Operators, Production Engineers, and more. Additionally, it helps drive progress towards the European Commission's goal of having a skilled workforce to support the European Union's Green Deal.